Suppr超能文献

恶性胶质瘤:谁能从辅助化疗中获益?

Malignant glioma: who benefits from adjuvant chemotherapy?

作者信息

DeAngelis L M, Burger P C, Green S B, Cairncross J G

机构信息

Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

出版信息

Ann Neurol. 1998 Oct;44(4):691-5. doi: 10.1002/ana.410440418.

Abstract

We combined two randomized prospective Brain Tumor Study Group data sets to analyze the effects of prognostic factors on survival by treatment group. Adjuvant chemotherapy increased long-term survival regardless of prognostic factors. Pathological review revealed that oligo dendrogliomas were overrepresented among long-term survivors independent of therapy. Prognostic factors do not predict benefit from adjuvant nitrosourea in malignant gliomas, and long-term survival with chemotherapy is not explained by oligodendroglial tumors.

摘要

我们合并了两个随机前瞻性脑肿瘤研究组的数据集,以按治疗组分析预后因素对生存的影响。无论预后因素如何,辅助化疗均可提高长期生存率。病理检查显示,少突胶质细胞瘤在长期存活者中所占比例过高,与治疗无关。预后因素无法预测恶性胶质瘤患者从辅助亚硝基脲治疗中是否获益,化疗后的长期生存也无法用少突胶质细胞瘤来解释。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验